Background Development of new, effective, and affordable tuberculosis (TB) therapies has
been identified as a critical priority for global TB control. As new candidates emerge from the …

Tuberculosis (TB) is a major threat to global health, recently exacerbated by the emergence
of highly drug-resistant forms of the disease-causing pathogen and synergy with HIV/AIDS …

Recent advances in the treatment of tuberculosis (TB) have led to improvements
unprecedented in our lifetime. Decades of research in developing new drugs, especially for …

Background Novel drug regimens are needed for tuberculosis (TB) treatment. New regimens
aim to improve on characteristics such as duration, efficacy, and safety profile, but no single …

Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium
tuberculosis. Despite decades of research driving advancements in drug development and …

Latent tuberculosis infection (LTBI) represents a subclinical, asymptomatic mycobacterial
state affecting approximately 25% of the global population. The substantial prevalence of …

Despite current control efforts, global tuberculosis (TB) incidence is decreasing slowly. New
regimens that can shorten treatment hold promise for improving treatment completion and …

NEW TOOLS to improve the treatment and control of tuberculosis (TB) are a critical
component of any comprehensive strategy to eradicate the global TB epidemic. In particular …

Background Tuberculosis (TB) is a global health challenge and one of the leading causes of
death worldwide. In the last decade, the TB treatment landscape has dramatically changed …

Tuberculosis (TB) is a leading cause of morbidity and mortality worldwide, accounting for
about 9.6 million new cases and 1.5 million deaths annually. The poorest and socially …